{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-25-000122","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.257872+00:00","generated_at":"2026-05-16T12:45:46.133217+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcus Biosciences amends loan agreement to access up to $150M tied to clinical and FDA milestones","bullets":["First Amendment to Loan and Security Agreement with Hercules Capital dated December 18, 2025.","Up to $50M available after announcement of Phase 3 data supporting FDA filing; $50M after FDA approval.","$50M available at company's sole option through March 2026 and September 2026 ($25M each).","Maturity extended to September 1, 2030.","Performance covenants apply if draws exceed $200M: market cap ≥ $1.5B or cash/revenue thresholds."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-25-000122","json":"https://secwatch.observer/filing/0001724521-25-000122.json","markdown":"https://secwatch.observer/filing/0001724521-25-000122.md","text":"https://secwatch.observer/filing/0001724521-25-000122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000122/0001724521-25-000122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000122/rcus-20251218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:45:46.133217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e02478d2561131b75c9e4ed150f2070ce0a174e6","claim":"Arcus Biosciences, Inc. amended credit facility of $150.0 million term loan commitments with Hercules Capital, Inc. maturing September 1, 2030.","evidence_excerpt":"Agreement, dated as of August 27, 2024, by and among the Company, Hercules and the Lenders (the “Loan Agreement”). The First Amendment amends the terms for the remaining $150.0 million term loan commitments available under the loan facility such that, subject to customary terms and conditions, (a) $25.0 million is available at the Company's sole option through","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000122/0001724521-25-000122-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$150.0 million term loan commitments"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Maturity","value":"September 1, 2030"},{"label":"Event","value":"amendment"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}